On October 19, 2026 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, reported it will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company’s website, located at investors.xencor.com. A recording will be available for at least 30 days.
ESMO Presentation to Highlight Results for Intravenous Doses Evaluated for Recommended Phase 3 Dose Selection in ccRCC
Results from the Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 being held in Madrid, Spain. Details of the presentation:
Title: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)
Session: Proffered paper 2: Genitourinary tumours, renal and urothelial
Session Date/Time: Sunday, October 25, 2026, 8:30 a.m. – 10:00 a.m. CET
Session Location: IFEMA Madrid, Almeria Auditorium – Hall 9
Presenter: Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs, City of Hope Comprehensive Cancer Center
XmAb819 Evaluation Across Advanced ccRCC and ENPP3+ Tumors
XmAb819 is being evaluated for the treatment of patients with advanced ccRCC and ENPP3+ tumors in a Phase 1 clinical study (Clinicaltrials.gov Identifier: NCT05433142). Xencor is planning to initiate a registration-enabling study of XmAb819 monotherapy in advanced ccRCC in 2027. Currently:
Expansion cohorts are evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC,
Dose escalation of subcutaneous administration in advanced ccRCC is ongoing,
A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma opened to enrollment in the second quarter of 2026, and
A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment (IO doublet therapy) opened to enrollment in the third quarter of 2026.
About XmAb819
XmAb819 is a first-in-class, tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC) and other tumors with high ENPP3 expression, including colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma. XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3. ENPP3 is a differentially expressed target, with high-level expression in renal cell carcinoma (RCC) and low-level expression on normal tissues. With two tumor-antigen binding domains and one T-cell binding domain, Xencor’s XmAb 2+1 format enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density, potentially sparing normal cells.
(Press release, Xencor, OCT 19, 2026, View Source [SID1234673591])